Literature DB >> 24649958

Early repositioning through compound set enrichment analysis: a knowledge-recycling strategy.

Gergely Temesi1, Bence Bolgár, Adám Arany, Csaba Szalai, Péter Antal, Péter Mátyus.   

Abstract

Despite famous serendipitous drug repositioning success stories, systematic projects have not yet delivered the expected results. However, repositioning technologies are gaining ground in different phases of routine drug development, together with new adaptive strategies. We demonstrate the power of the compound information pool, the ever-growing heterogeneous information repertoire of approved drugs and candidates as an invaluable catalyzer in this transition. Systematic, computational utilization of this information pool for candidates in early phases is an open research problem; we propose a novel application of the enrichment analysis statistical framework for fusion of this information pool, specifically for the prediction of indications. Pharmaceutical consequences are formulated for a systematic and continuous knowledge recycling strategy, utilizing this information pool throughout the drug-discovery pipeline.

Mesh:

Substances:

Year:  2014        PMID: 24649958     DOI: 10.4155/fmc.14.4

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  3 in total

Review 1.  Drug repositioning for gynecologic tumors: a new therapeutic strategy for cancer.

Authors:  Kouji Banno; Miho Iida; Megumi Yanokura; Haruko Irie; Kenta Masuda; Yusuke Kobayashi; Eiichiro Tominaga; Daisuke Aoki
Journal:  ScientificWorldJournal       Date:  2015-02-03

Review 2.  "Omics"-Informed Drug and Biomarker Discovery: Opportunities, Challenges and Future Perspectives.

Authors:  Holly Matthews; James Hanison; Niroshini Nirmalan
Journal:  Proteomes       Date:  2016-09-12

3.  VB-MK-LMF: fusion of drugs, targets and interactions using variational Bayesian multiple kernel logistic matrix factorization.

Authors:  Bence Bolgár; Péter Antal
Journal:  BMC Bioinformatics       Date:  2017-10-04       Impact factor: 3.169

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.